ApprovalTrail

Approval · Notice of Compliance 21726 · 2019

DUTASTERIDE: Notice of Compliance 21726

Issued January 10, 2019

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
21726
Date
January 10, 2019
Company
Pro Doc LimiteeLaval, Quebec, Canada
Product type
Prescription Pharmaceutical
Submission
Abbreviated New Drug Submission (ANDS)
Submission class
Admin
Reason
Licensing agreemeent between two companies
Canadian reference product
AVODART (Glaxosmithkline Inc)

Products in this notice

BrandDINStatus today
DUTASTERIDE02421712Cancelled Post Market

Medicinal ingredients